

# May 2012 DUR Board PDL Meeting Minutes

**Date:** May 23, 2012

**Members Present:** Wilkinson, Brown, Bradley, Burton, Crichton, Caldwell, Putsch, Fitzgerald, Cobb (phone), Maxwell (phone)

**Others Present:** Dan Peterson, Amy Holodnick, Dave Campana (Medicaid), Kathy Novak (Magellan), Woodmansey and Barnhill (Drug PA/CM unit), and various members of the public and representatives of drug manufacturers.

Lisa called the meeting to order.

**Public Comment Period:** No one offered public comment at this time.

The April DUR Board meeting minutes were reviewed and approved. Discussion was held about category expansion and clarification for the future.

## **Department Update:**

Dave Campana informed the Board the simvastatin 80mg limit previously approved was ready to be implemented. He also made the Board aware the new family planning waiver is set to begin.

## **PDL Review:**

The Department reviewed the following classes as **NEW** information is known to exist. The Board made the following recommendations to the Department:

- ACNE AGENTS – Category expansion
  - *BENZOYL PEROXIDE COMBOS* – Class Effect.
  - *BENZOYL PEROXIDE AGENTS* – Class Effect.
  - *CLINDAMYCIN AGENTS* – Class Effect.
  - *SODIUM SULFACETAMIDE AGENTS* – Class Effect.
  - *AZELAIC ACID* – May add.
  - *DAPSONE TOPICAL* – May add.
  - *TOPICAL RETINOIDS & Combos* – Class Effect – Grandfather.
  - *ERYTHROMYCIN TOPICAL* – Class Effect.
- ANTIFUNGALS, ORAL – Category expansion.  
Must have terbinafine; May add itraconazole and griseofulvin for Onychomycosis.  
Must have fluconazole; Must have 1 of clotrimazole or nystatin; May add others.  
May add PA criteria.
- ANTIVIRALS, TOPICAL (new category)- Class Effect.
- BPH AGENTS –
  - *ALPHA BLOCKERS* – Class Effect.
  - *ANDROGEN HORMONE INHIBITORS AND COMBOS* – Class Effect.
  - *PDE5 for BPH* – Tadalafil (Cialis®) will be non-preferred with PA criteria.
- IMMUNOMODULATORS – Therapeutic alternatives; Do not add Anakinra (Kineret®), PA Criteria, Grandfather.
- FLUOROQUINOLONES, ORAL –
  - *2<sup>nd</sup> Gen*- Must have ciprofloxacin; Others are class effect, may add.
- *3<sup>rd</sup> Gen*- Must have levofloxacin; Others are class effect, may add.
- HEPATITIS C AGENTS – Grandfather.
  - *RIBIVIRINS* – Class Effect.
  - *PEGYLATED INTERFERON* – Class Effect.

- *PROTEASE INHIBITORS* – Must have telaprevir (Incivek®); may add boceprevir (Victrelis®).
- IMMUNOSUPPRESSANTS – Full review has not been held. It will be done in 2013. All chemical entities will be available as preferred. Everolimus (Zortress®) will be preferred; add PA Criteria for kidney transplant.
- INTRANASAL RHINITIS AGENTS
  - *NASAL CORTICOSTEROIDS* – Class Effect.
  - *NASAL ANTIHISTAMINES* – Class Effect.
  - *NASAL RHINITIS OTHER* – Must have an ipratropium product.
- MACROLIDES & KETOLIDES – Class Effect; must have azithromycin, clarithromycin, erythromycin.
- TOPICAL STEROIDS – New Category
  - *LOW POTENCY* – Class Effect; must have 1 cream and 1 ointment, may add other forms.
  - *MEDIUM POTENCY* – Class Effect; must have 1 cream and 1 ointment, may add other forms.
  - *HIGH POTENCY* – Class Effect; must have 1 cream and 1 ointment, may add other forms.
  - *VERY HIGH POTENCY* – Class Effect; must have 1 cream and 1 ointment, may add other forms.

The Department proposed no changes to the Formulary Committee's previous clinical recommendations.

(The following classes were not reviewed because no **NEW** information was submitted.)

The Board made the following recommendations to the Department:

- MINIMALLY SEDATING ANTIHISTAMINES and DECONGESTANT COMBOS  
Category name change  
Must have 1 single ingredient agent.
- BLADDER RELAXANTS – Must have 1 long acting agent (either by half-life or dosage form).
- CEPHALOSPORINS & Related Antibiotics –
  - *2<sup>nd</sup> GENERATION* – Class effect
  - *3<sup>RD</sup> GENERATION* – Class effect
- COPD AGENTS – Grandfather.  
Must have ipratropium in some form; may add tiotropium; may add roflumilast (Daliresp®).
- HERPETIC ANTIVIRALS – Class effect
- INHALED GLUCOCORTICOIDS & COMBOS – Class effect
- LABA INHALERS & NEBS – Class effect. Must have 1 inhaler form.
- SABA INHALERS & NEBS – Class effect. Grandfathered (by chemical entity, not brand).
- LEUKOTRIENE MODIFIERS – Must have montelukast (Singulair®); may add zafirlukast.
- TOPICAL ANTIBIOTICS – Must have a mupirocin product; may have retapamulin (Altabax®).

- TOPICAL IMMUNOMODULATORS – Class effect. Must have one. PA requirements are in place.

There were no green classes for this meeting

The next meeting will be Wednesday June 27, 2012, at The Great Northern Hotel.  
The meeting was adjourned at 4:10.